Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cash, R.
Right arrow Articles by Scatton, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cash, R.
Right arrow Articles by Scatton, B.
NEUROLOGY 1987;37:42
© 1987 American Academy of Neurology

Parkinson's disease and dementia

Norepinephrine and dopamine in locus ceruleus

R. Cash, T. Dennis, R. L'Heureux, R. Raisman, F. Javoy-Agid and B. Scatton

INSERM U 289 (Drs. Cash, Raisman. and Javoy-Agid), CHU Pitié-Salpétrière, Paris; and the Biochemical Pharmacology Group (Drs. Dennis, L'Heureux, and Scatton), Laboratoires d'Etudes et de Recherches Synthelabo, Bagmux, France.

Norepinephrine, 3-methoxy 4-hydroxyphenylethyleneglycol and homovanillic acid levels were similar in the locus ceruleus of 13 controls and 8 parkinsonian patients with no intellectual deterioration, but were decreased in 7 demented patients. The concentration of dopamine was similarly diminished in non-demented and demented parkinsonians, and binding of,4H-desmethylimipramine and :'H-rauwolscine was not abnormal in parkinsonians. These data indicate that norepinephrine metabolism in the locus ceruleus is subnormal only in demented parkinsonians.

Address correspondence and reprint requests to Dr. Cash, INSERM U 289, CHU Pitié-Salpérière, 91 Boulevard de l'Hôpital, 75634 Paris, Cedex 13, France.

Received January 30, 1986. Accepted for publication April 14, 1986.




This article has been cited by other articles:


Home page
 Proc. Natl. Acad. Sci. USAHome page
K. S. Rommelfanger, G. L. Edwards, K. G. Freeman, L. C. Liles, G. W. Miller, and D. Weinshenker
Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice
PNAS, August 21, 2007; 104(34): 13804 - 13809.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
S J G Lewis, T Foltynie, A D Blackwell, T W Robbins, A M Owen, and R A Barker
Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach
J. Neurol. Neurosurg. Psychiatry, March 1, 2005; 76(3): 343 - 348.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
K Walsh and G Bennett
Parkinson's disease and anxiety
Postgrad. Med. J., February 1, 2001; 77(904): 89 - 93.
[Abstract] [Full Text]

Home page
 PsychosomaticsHome page
L. Marsh
Neuropsychiatric Aspects of Parkinson's Disease
Psychosomatics, February 1, 2000; 41(1): 15 - 23.
[Abstract] [Full Text]

Home page
 J Geriatr Psychiatry NeurolHome page
J. L. Cummings
Intellectual Impairment in Parkinson's Disease: Clinical, Pathologic, and Biochemical Correlates
J Geriatr Psychiatry Neurol, January 1, 1988; 1(1): 24 - 36.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1987 by AAN Enterprises, Inc.